Initial studies performed with ErbB2-, CD20-, and GD2-targeted CAR NK-92 cells showed that these cells retain specific cytotoxicity in simplified in vivo models in immunocompromised nude and NOD-SCID IL2R γnull (NSG) mice, where effector cells were either subcutaneously coinjected together with tumor cells, or established subcutaneous tumors treated by peritumoral NK-cell injection. Here, ERBB2 is linked to neoplasm.